Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2022 | Role of the addition of docetaxel to ADT in mHSPC

Joe O’Sullivan, MD, Queen’s University, Belfast, UK, provides an overview of the role of doublet and triplet therapy in the management of patients with metastatic hormone-sensitive prostate cancer (mHSPC), highlighting the improved responses seen with docetaxel in combination with androgen deprivation therapy (ADT). This interview took place at the European Association of Urology (EAU) Meeting 2022.


Prof. O’Sullivan reports the following conflicts of interest:
Personal fees for Advisory Board and Speaker’s bureau from: AAA/Novartis, Astellas, Bayer, Janssen, Sanofi